Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for protection against chemotherapy-related ovarian injury in adolescent girls with malignant tumors
ChiCTR1900023489Phase 4Not yet recruiting
- Sponsor
- Tongji Medical College
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ovarian injury and female reproductive toxicity comparing Placebo + chemotherapy with Metformin + chemotherapy (2 arms). Primary endpoint: Anti-Mullerian hormone. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
ovarian injuryfemale reproductive toxicity
Beyond the preview
Go deeper on ChiCTR1900023489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023489.